Video

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup Analysis

Author(s):

Thomas Martin, MD, University of California San Francisco

Expert hematologist-oncologist Thomas G. Martin, MD, shares data from the IKEMA subgroup analysis in patients with relapsed multiple myeloma treated with isatuximab, carfilzomib, and dexamethasone.

Related Videos
C. Ola Landgren, MD, PhD
David Samuel Dicapua Siegel, MD
Management of Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoietin Stimulating Agent (ESA) Treatment
Alfred L. Garfall, MD, MS
Noa Biran, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Noa Biran, MD
Alfred L. Garfall, MD, MS
Amrita Krishnan, MD, City of Hope
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study
Related Content
Image Credit: ©Dr_Microbe - stock.adobe.com
July 19th 2024

EMA Accepts MAA for Belantamab Mafodotin Combos in R/R Multiple Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

C. Ola Landgren, MD, PhD, professor, medicine, chief, Division of Myeloma, Department of Medicine, director, Sylvester Myeloma Institute, co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in Immunotherapy, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
July 18th 2024

Quadruplet Regimens Revive Newly Diagnosed Multiple Myeloma Treatment

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Noa Biran, MD
July 9th 2024

Myeloma Data Presented at ASCO Highlight Continued Evolution of Treatment Paradigm

Ying Huang, PhD
July 2nd 2024

Cilta-Cel Generates OS Benefit in R/R Myeloma After 1 Prior Therapy